HC Wainwright Decreases Earnings Estimates for Verona Pharma

Verona Pharma plc (NASDAQ:VRNA) – Equities researchers at HC Wainwright reduced their Q4 2025 EPS estimates for Verona Pharma in a research note issued on Wednesday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.02 per share for the quarter, down from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($1.95) per share.

A number of other research firms have also recently commented on VRNA. Cantor Fitzgerald began coverage on Verona Pharma in a research note on Monday, April 21st. They set an “overweight” rating and a $80.00 target price on the stock. Roth Mkm started coverage on shares of Verona Pharma in a research report on Friday, January 10th. They issued a “buy” rating and a $68.00 price objective on the stock. TD Cowen initiated coverage on shares of Verona Pharma in a research note on Monday. They issued a “buy” rating and a $100.00 target price on the stock. Wells Fargo & Company raised their price target on shares of Verona Pharma from $93.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Roth Capital set a $83.00 price target on shares of Verona Pharma in a report on Friday, February 28th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $81.50.

Verona Pharma Stock Performance

Shares of Verona Pharma stock opened at $72.26 on Thursday. The business’s fifty day simple moving average is $62.89 and its 200 day simple moving average is $51.63. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma has a 12 month low of $11.39 and a 12 month high of $74.18. The firm has a market capitalization of $5.84 billion, a P/E ratio of -37.64 and a beta of 0.16.

Verona Pharma (NASDAQ:VRNA) last posted its earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million.

Institutional Trading of Verona Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of VRNA. NBC Securities Inc. purchased a new position in shares of Verona Pharma during the 1st quarter valued at $34,000. Vermillion Wealth Management Inc. bought a new stake in Verona Pharma during the fourth quarter valued at $46,000. GF Fund Management CO. LTD. purchased a new position in Verona Pharma during the fourth quarter worth about $72,000. GAMMA Investing LLC increased its stake in Verona Pharma by 20.7% in the 4th quarter. GAMMA Investing LLC now owns 1,612 shares of the company’s stock worth $75,000 after acquiring an additional 276 shares during the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of Verona Pharma in the 1st quarter valued at about $100,000. Institutional investors own 85.88% of the company’s stock.

Insider Activity at Verona Pharma

In related news, General Counsel Andrew Fisher sold 26,072 shares of the stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total transaction of $234,126.56. Following the sale, the general counsel now owns 359,993 shares of the company’s stock, valued at approximately $3,232,737.14. This represents a 6.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Vikas Sinha sold 20,000 shares of Verona Pharma stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $8.92, for a total value of $178,400.00. Following the transaction, the director now directly owns 74,440 shares of the company’s stock, valued at $664,004.80. The trade was a 21.18 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 250,080 shares of company stock worth $2,194,582. 4.80% of the stock is owned by corporate insiders.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.